Testing lenalidomide with EPOCH for adult T-cell leukemia-lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests whether adding lenalidomide to a standard chemotherapy regimen (EPOCH) helps people with adult T-cell leukemia-lymphoma (ATLL). It aims to improve how well the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have adult T-cell leukemia-lymphoma (ATLL).
- You are at least 18 years old.
- You are reasonably active (able to care for yourself, up and about).
- Your blood counts and organ function (kidney/liver) are within acceptable limits.
- If you are a woman who can become pregnant, you agree to use highly effective birth control and have regular pregnancy tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs for people newly diagnosed with a rare and aggressive type of T-cell acute lymphoblastic leukemia (ETP-ALL). The goal is to see if this combination can help put the leukemia into remission.
This trial tests two drugs, azacitidine and abatacept, given together for T-cell lymphoma that has come back or not improved after earlier treatment. The goal is to see if this combination can control the cancer better, potentially offering a new option for patients.
This trial tests whether high-dose chemotherapy followed by a stem cell transplant using your own cells can help people with certain types of peripheral T-cell lymphoma live longer. You would qualify if you have already finished your first round of chemotherapy and are in complete remission.
This Phase 2 trial compares two chemotherapy approaches—adding lenalidomide to CHOP versus CHOP alone—for people with untreated peripheral T-cell lymphoma (PTCL). The goal is to see if the added medicine improves response and safety.
This early-phase study tests whether lenalidomide combined with R-DA-EPOCH can treat untreated diffuse large B-cell lymphoma (DLBCL) that has a MYC rearrangement. It may help control the lymphoma, but it’s also designed to find the safest and most effective dosing.
This trial tests a combination of two drugs, epcoritamab and lenalidomide, for patients with a rare type of large B-cell lymphoma linked to a weakened immune system. It is for people whose lymphoma did not improve or returned after standard treatments, and who cannot get CAR-T therapy.
Hear when a new Adult T-cell Leukemia/Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.